View Older Stories View More Recent Stories

Apr 25, 2023 08:30AM Artelo Biosciences Initiates the Phase 2a Portion of its CAReS Trial EvaluatingART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss
Mar 31, 2023 08:00AM Artelo Biosciences Reports Fiscal 2022 Year-End Financial Results and Provides Business Update
Feb 15, 2023 08:30AM Artelo Biosciences to Present at MicroCap Rodeo’s Annual Winter Wonderland – Best Ideas Virtual Investor Conference on February 22, 2023
Feb 2, 2023 09:00AM Artelo Biosciences Completes Enrollment of the Phase 1b Stage of its CAReS Clinical Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss
Jan 26, 2023 08:30AM Artelo Biosciences to Present at Sequire Biotechnology Conference on February 2nd
Nov 8, 2022 08:00AM Artelo Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update
Oct 18, 2022 08:30AM Artelo Biosciences to Present at The LD Micro Main Event XV
Sep 22, 2022 09:00AM Artelo Biosciences to Present at the 2022 Ladenburg Thalmann Healthcare Conference on September 29th
Sep 7, 2022 08:30AM Artelo Biosciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Aug 16, 2022 09:00AM Artelo Biosciences Reports Positive Pre-Clinical Results with its Novel Inhibitor to Fatty Acid Binding Protein 5
Aug 9, 2022 08:10AM Artelo Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update
Jul 19, 2022 09:07AM Artelo Biosciences Completes Enrollment of the First Three Cohorts in its CAReS Study Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss
Jun 27, 2022 08:30AM Artelo Biosciences Presents Positive Pre-Clinical Results of ART26.12, a Novel FABP5 Inhibitor, in Alleviating Chemotherapy-Induced Pain
Jun 24, 2022 08:30AM Artelo Biosciences Selected for Oral Presentation at the 32nd Annual ICRS Symposium in Galway, Ireland
Jun 1, 2022 08:30AM Artelo Biosciences to Present at the LD Micro Invitational XII on June 7th
May 16, 2022 08:55AM Artelo Biosciences to Present at the H.C. Wainwright Global Investment Conference on May 24th
May 13, 2022 08:30AM Artelo Biosciences to Present at MicroCap Rodeo’s Spring into Action Best Ideas Virtual Conference on May 16th
May 12, 2022 08:30AM Artelo Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update
Apr 26, 2022 07:33AM Artelo Biosciences to Present at Investor Summit Group's Q2 In-Person Conference in New York
Apr 25, 2022 07:30AM Artelo Biosciences to Present at Investor Summit Group's Q2 In-Person Conference in New York
Apr 13, 2022 08:31AM Artelo Biosciences (ARTL) Reports Positive Pre-clinical Results for Lead Program in Cancer-Related Cachexia
Apr 13, 2022 08:30AM Artelo Biosciences Reports Positive Pre-clinical Results for Lead Program in Cancer-Related Cachexia
Mar 28, 2022 09:25AM Artelo Expands Collaboration with Trinity College Dublin to Investigate Cellular Biology of Fatty Acid Binding Protein (FABP) Inhibition In Cancer
Mar 22, 2022 09:00AM Artelo Biosciences to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th – 30th
Mar 21, 2022 08:30AM Artelo Biosciences Reports Four-Month 2021 Financial Results in Connection with its Amended Fiscal Year End and Provides Business Update
Mar 2, 2022 08:32AM Aristotle (ARTL) Receives Notice of Allowance for Method-of-Use Patent in the United States for ART12.11, a Proprietary Cocrystal of Cannabidiol
Mar 2, 2022 08:30AM Artelo Biosciences Receives Notice of Allowance for Method-of-Use Patent in the United States for ART12.11, a Proprietary Cocrystal of Cannabidiol
Jan 12, 2022 08:34AM Aristotle (ARTL) Reports Q1 Results, Provides Business Update
Jan 12, 2022 08:30AM Artelo Biosciences Reports First Quarter Fiscal Year 2022 Financial Results and Provides Business Update
Jan 11, 2022 08:35AM Aristotle (ARTL) Anticipates Accelerated Clinical Development for ART27.13 Following Its Classification Change in the United Kingdom
Jan 11, 2022 08:30AM Artelo Anticipates Accelerated Clinical Development for ART27.13 Following Its Classification Change in the United Kingdom
Jan 10, 2022 09:00AM Artelo Biosciences Leadership to Participate on Endocannabinoid Panel at the H.C. Wainwright BioConnect 2022 Virtual Conference
Nov 29, 2021 08:30AM Artelo Biosciences Reports Fiscal 2021 Year-End Financial Results and Provides Business Update
Nov 11, 2021 08:30AM Artelo Biosciences to Present at the Q4 Investor Summit on November 17th
Sep 8, 2021 08:30AM Artelo Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Aug 11, 2021 04:18PM Artelo Biosciences to Present at the Q3 Virtual Investor Summit on August 18th
Aug 4, 2021 08:34AM Aristotle (ARTL) Announces Publication of Study Results Comparing the Pharmacological Effects of Plant-Derived Versus Synthetic Cannabidiol in Human Cell Lines
Aug 4, 2021 08:30AM Artelo Biosciences Announces Publication of Study Results Comparing the Pharmacological Effects of Plant-Derived Versus Synthetic Cannabidiol in Human Cell Lines
Jul 21, 2021 08:30AM Ladenburg Thalmann to Host R&D Showcase Featuring Artelo Biosciences’ CAReS Study on July 28, 2021
Jul 12, 2021 08:30AM Artelo Biosciences Reports Third Quarter Fiscal 2021 Financial Results and Provides Business Update
Jul 7, 2021 08:30AM Artelo Biosciences to Present at the 2021 Ladenburg Thalmann Healthcare Conference on July 14th
Jun 22, 2021 08:00AM Artelo Biosciences Announces Two Poster Presentations Featured at the 31st Annual ICRS Symposium
Jun 2, 2021 08:30AM Artelo Biosciences to Present at the LD Micro Virtual Invitational XI on June 9th
May 6, 2021 07:00AM Artelo Biosciences to Participate at the Benzinga Global Small Cap Conference on May 13, 2021
Apr 13, 2021 08:30AM Artelo Biosciences Reports Second Quarter Fiscal 2021 Financial Results and Provides Business Update
Apr 12, 2021 08:35AM Aristotle (ARTL) Reports First Patient in CAReS Study with ART27.13 for Treatment of Cancer-Related Anorexia and Weight Loss
Apr 12, 2021 08:30AM Artelo Biosciences Doses First Patient in CAReS Study with ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss
Mar 19, 2021 10:00AM Artelo Biosciences Accepted into the Alderley Park Oncology Development Program for FABP5 Inhibitor Biomarker Development
Mar 11, 2021 07:10AM Artelo Biosciences, Inc. to Present at the Q1 Virtual Investor Summit on March 23rd
Mar 9, 2021 08:30AM Artelo Biosciences Appoints Finance and Healthcare Industry Executive Tamara A. Seymour to Board of Directors
View More Recent Stories View Older Stories